AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
AMED gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. While AMED has a great profitability rating, there are some minor concerns on its financial health. AMED is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AMED was profitable.
In the past year AMED had a positive cash flow from operations.
AMED had positive earnings in 4 of the past 5 years.
Each year in the past 5 years AMED had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.11%, AMED is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
With a decent Return On Equity value of 7.49%, AMED is doing good in the industry, outperforming 67.65% of the companies in the same industry.
AMED's Return On Invested Capital of 10.15% is amongst the best of the industry. AMED outperforms 81.37% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMED is in line with the industry average of 9.62%.
The last Return On Invested Capital (10.15%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROIC | 10.15% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
With a decent Profit Margin value of 3.79%, AMED is doing good in the industry, outperforming 71.57% of the companies in the same industry.
AMED's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 9.17%, AMED is doing good in the industry, outperforming 79.41% of the companies in the same industry.
AMED's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 43.37%, AMED is doing good in the industry, outperforming 72.55% of the companies in the same industry.
In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
AMED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMED has more shares outstanding
Compared to 1 year ago, AMED has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.92 indicates that AMED is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.92, AMED is doing good in the industry, outperforming 75.49% of the companies in the same industry.
The Debt to FCF ratio of AMED is 1.69, which is an excellent value as it means it would take AMED, only 1.69 years of fcf income to pay off all of its debts.
AMED has a Debt to FCF ratio of 1.69. This is amongst the best in the industry. AMED outperforms 84.31% of its industry peers.
AMED has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.28, AMED is doing good in the industry, outperforming 65.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 3.92 |
ROIC/WACC1.15
WACC8.81%
2.3 Liquidity
A Current Ratio of 1.29 indicates that AMED should not have too much problems paying its short term obligations.
The Current ratio of AMED (1.29) is comparable to the rest of the industry.
AMED has a Quick Ratio of 1.29. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED has a Quick ratio (1.29) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
AMED shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.86%.
AMED shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.46% yearly.
Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 5.34% in the last year.
The Revenue has been growing slightly by 3.73% on average over the past years.
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
3.2 Future
AMED is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.37% yearly.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 4.80% on average per year.
EPS Next Y12.77%
EPS Next 2Y11.59%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 21.50, which indicates a rather expensive current valuation of AMED.
68.63% of the companies in the same industry are more expensive than AMED, based on the Price/Earnings ratio.
AMED's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.53.
With a Price/Forward Earnings ratio of 18.15, AMED is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 65.69% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.27. AMED is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.5 | ||
| Fwd PE | 18.15 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than the industry average as 65.69% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than 78.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.62 | ||
| EV/EBITDA | 11.41 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.68
PEG (5Y)N/A
EPS Next 2Y11.59%
EPS Next 3Y7.37%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AMED (6/10/2025, 11:24:13 AM)
97.4
+3.18 (+3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.9%
Inst Owner Change-1.69%
Ins Owners1.76%
Ins Owner Change5.16%
Market Cap3.20B
Analysts53.75
Price Target102.85 (5.6%)
Short Float %6.29%
Short Ratio5.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-10.15%
Max EPS beat(2)12.12%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-15.99%
Max EPS beat(4)12.12%
EPS beat(8)3
Avg EPS beat(8)-0.55%
EPS beat(12)6
Avg EPS beat(12)2.46%
EPS beat(16)8
Avg EPS beat(16)2.78%
Revenue beat(2)0
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-2.05%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-1.99%
Revenue beat(12)1
Avg Revenue beat(12)-2.69%
Revenue beat(16)1
Avg Revenue beat(16)-2.79%
PT rev (1m)4.85%
PT rev (3m)3.55%
EPS NQ rev (1m)0.47%
EPS NQ rev (3m)-5.4%
EPS NY rev (1m)1.47%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-0.37%
Revenue NQ rev (3m)-1.51%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.5 | ||
| Fwd PE | 18.15 | ||
| P/S | 1.35 | ||
| P/FCF | 14.62 | ||
| P/OCF | 14.24 | ||
| P/B | 2.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.41 |
EPS(TTM)4.53
EY4.65%
EPS(NY)5.37
Fwd EY5.51%
FCF(TTM)6.66
FCFY6.84%
OCF(TTM)6.84
OCFY7.02%
SpS72.26
BVpS36.55
TBVpS-2.88
PEG (NY)1.68
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROCE | 12.85% | ||
| ROIC | 10.15% | ||
| ROICexc | 12.2% | ||
| ROICexgc | 151.22% | ||
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% | ||
| FCFM | 9.22% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 9.64% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 7.77 | ||
| Cash Conversion | 80.59% | ||
| Profit Quality | 243.34% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.92 |
F-Score7
WACC8.81%
ROIC/WACC1.15
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
EPS Next Y12.77%
EPS Next 2Y11.59%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
EBIT growth 1Y18.92%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year18.26%
EBIT Next 3Y9.99%
EBIT Next 5YN/A
FCF growth 1Y112.26%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y102.82%
OCF growth 3Y5.48%
OCF growth 5Y1.88%